In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases

阿兹屈南 铜绿假单胞菌 微生物学 最小抑制浓度 生物 细菌 抗生素 头孢他啶 遗传学
作者
Christophe Le Terrier,Patrice Nordmann,Laurent Poirel
出处
期刊:Journal of Antimicrobial Chemotherapy [Oxford University Press]
卷期号:78 (1): 101-107 被引量:13
标识
DOI:10.1093/jac/dkac360
摘要

To evaluate the in vitro activity of aztreonam in combination with novel β-lactamase inhibitors, namely avibactam, nacubactam, taniborbactam and zidebactam, against MDR MBL-producing Enterobacterales and Pseudomonas aeruginosa clinical isolates.MIC values of aztreonam, aztreonam/β-lactam inhibitor but also cefiderocol as comparator were determined for 64 and 39 clinical Enterobacterales or P. aeruginosa isolates, respectively, producing representative MBLs, i.e. derivatives of NDM (n = 64), VIM (n = 32), IMP (n = 8) and SPM (n = 2). MICs were also determined for Escherichia coli TOP10 and P. aeruginosa PAO1 harbouring recombinant plasmids producing the different β-lactamases under isogenic backgrounds (n = 22 and n = 11, respectively). Fifty percent inhibitory concentrations were additionally determined for the abovementioned β-lactamase inhibitors using β-lactamase crude extracts.The susceptibility rate for aztreonam was 17.1% among MBL-producing Enterobacterales, while it was very high with aztreonam/zidebactam (98.4%), and to a lower extent with aztreonam/nacubactam (84.4%) and aztreonam/taniborbactam (75%), compared with aztreonam/avibactam (70.3%) and cefiderocol (39.1%). Among MBL-producing P. aeruginosa isolates, the susceptibility rates were 53.8% with aztreonam, 66.7% with aztreonam/nacubactam and aztreonam/taniborbactam combinations, and 69.2% with aztreonam/avibactam, aztreonam/zidebactam and cefiderocol.Altogether, these results showed that combinations including aztreonam and novel β-lactamase inhibitors, such as zidebactam, nacubactam or taniborbactam, have a very significant in vitro activity against MDR MBL-producing Enterobacterales clinical isolates, the aztreonam/zidebactam combination being the best option. On the other hand, aztreonam/zidebactam is equivalent to aztreonam/avibactam and cefiderocol among MBL-producing P. aeruginosa isolates.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
haha发布了新的文献求助10
刚刚
Orange应助科研通管家采纳,获得10
刚刚
美含完成签到,获得积分10
刚刚
JamesPei应助科研通管家采纳,获得10
刚刚
完美世界应助花生采纳,获得10
刚刚
phc完成签到,获得积分20
刚刚
斯文败类应助科研通管家采纳,获得10
刚刚
斯文败类应助科研通管家采纳,获得10
刚刚
刚刚
大模型应助科研通管家采纳,获得10
刚刚
1秒前
王为云完成签到,获得积分10
1秒前
香蕉觅云应助科研通管家采纳,获得10
1秒前
缺粥发布了新的文献求助10
1秒前
聪明惊蛰完成签到,获得积分10
1秒前
1秒前
1秒前
传奇3应助科研通管家采纳,获得10
1秒前
烟花应助泡椒采纳,获得10
1秒前
2秒前
年轻龙猫应助郭书磊采纳,获得10
2秒前
lly完成签到,获得积分10
2秒前
2秒前
李健的小迷弟应助phc采纳,获得10
3秒前
4秒前
葡萄树完成签到,获得积分10
5秒前
情怀应助陈椅子的求学采纳,获得10
5秒前
5秒前
染染完成签到,获得积分10
5秒前
科研通AI6.2应助coco采纳,获得10
6秒前
6秒前
田様应助xlnju采纳,获得10
6秒前
李美玥完成签到 ,获得积分10
6秒前
Li完成签到,获得积分10
7秒前
7秒前
斯文败类应助涛涛采纳,获得10
7秒前
aaaa应助AC咪咪采纳,获得30
8秒前
8秒前
佳佳完成签到,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Principles of town planning: translating concepts to applications 1000
2016 Venous Blood Study (VBS) (Final V3.0) 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
核安全综合知识2024版 500
Photothermal Science and Techniques 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7703733
求助须知:如何正确求助?哪些是违规求助? 9261995
关于积分的说明 20034713
捐赠科研通 7279297
什么是DOI,文献DOI怎么找? 3294655
关于科研通互助平台的介绍 2449871
邀请新用户注册赠送积分活动 2301447